280 related articles for article (PubMed ID: 26625717)
1. PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.
Belletti D; Tosi G; Forni F; Lagreca I; Barozzi P; Pederzoli F; Vandelli MA; Riva G; Luppi M; Ruozi B
Eur J Pharm Biopharm; 2016 Feb; 99():7-17. PubMed ID: 26625717
[TBL] [Abstract][Full Text] [Related]
2. PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness.
Lechanteur A; Furst T; Evrard B; Delvenne P; Hubert P; Piel G
Eur J Pharm Sci; 2016 Oct; 93():493-503. PubMed ID: 27593989
[TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
[TBL] [Abstract][Full Text] [Related]
4. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.
Li Y; Cheng Q; Jiang Q; Huang Y; Liu H; Zhao Y; Cao W; Ma G; Dai F; Liang X; Liang Z; Zhang X
J Control Release; 2014 Feb; 176():104-14. PubMed ID: 24365128
[TBL] [Abstract][Full Text] [Related]
5. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
6. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
[TBL] [Abstract][Full Text] [Related]
7. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.
Li Y; Liu R; Shi Y; Zhang Z; Zhang X
Theranostics; 2015; 5(6):583-96. PubMed ID: 25825598
[TBL] [Abstract][Full Text] [Related]
8. Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution in mice.
Hattori Y; Tamaki K; Sakasai S; Ozaki KI; Onishi H
Mol Med Rep; 2020 Nov; 22(5):4183-4196. PubMed ID: 33000194
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of siRNA lipoplexes: Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study.
Khatri N; Baradia D; Vhora I; Rathi M; Misra A
AAPS PharmSciTech; 2014 Dec; 15(6):1630-43. PubMed ID: 25145330
[TBL] [Abstract][Full Text] [Related]
10. Post-pegylated lipoplexes are promising vehicles for gene delivery in RPE cells.
Peeters L; Sanders NN; Jones A; Demeester J; De Smedt SC
J Control Release; 2007 Aug; 121(3):208-17. PubMed ID: 17630013
[TBL] [Abstract][Full Text] [Related]
11. Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
Resnier P; LeQuinio P; Lautram N; André E; Gaillard C; Bastiat G; Benoit JP; Passirani C
Biotechnol J; 2014 Nov; 9(11):1389-401. PubMed ID: 25262914
[TBL] [Abstract][Full Text] [Related]
12. Stealth monoolein-based nanocarriers for delivery of siRNA to cancer cells.
Oliveira AC; Raemdonck K; Martens T; Rombouts K; Simón-Vázquez R; Botelho C; Lopes I; Lúcio M; González-Fernández Á; Real Oliveira ME; Gomes AC; Braeckmans K
Acta Biomater; 2015 Oct; 25():216-29. PubMed ID: 26225736
[TBL] [Abstract][Full Text] [Related]
13. Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Forouzanfar T; Helder MN; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):684-692. PubMed ID: 29475393
[TBL] [Abstract][Full Text] [Related]
14. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS.
Cardoso AL; Simões S; de Almeida LP; Plesnila N; Pedroso de Lima MC; Wagner E; Culmsee C
J Control Release; 2008 Dec; 132(2):113-23. PubMed ID: 18796321
[TBL] [Abstract][Full Text] [Related]
15. Effect of PEG anchor in PEGylation of folate-modified cationic liposomes with PEG-derivatives on systemic siRNA delivery into the Tumor.
Tang M; Sakasai S; Onishi H; Kawano K; Hattori Y
J Drug Target; 2023 Jan; 31(1):74-88. PubMed ID: 35864749
[TBL] [Abstract][Full Text] [Related]
16. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
17. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy.
Lee J; Ahn HJ
Biochem Biophys Res Commun; 2018 Sep; 503(3):1716-1722. PubMed ID: 30049442
[TBL] [Abstract][Full Text] [Related]
18. Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery.
Berger M; Toussaint F; Djemaa SB; Laloy J; Pendeville H; Evrard B; Jerôme C; Lechanteur A; Mottet D; Debuigne A; Piel G
J Control Release; 2023 Sep; 361():87-101. PubMed ID: 37482343
[TBL] [Abstract][Full Text] [Related]
19. Transfection efficacy and drug release depends upon the PEG derivative in cationic lipoplexes: Evaluation in 3D in vitro model and in vivo.
A M G; O O K; A S N; L I V; V A S; L A K; E A E; V V S; U A B; Yu L S; N E S; M R K; E M
J Biomed Mater Res B Appl Biomater; 2023 Sep; 111(9):1614-1628. PubMed ID: 37132593
[TBL] [Abstract][Full Text] [Related]
20. Control of cell penetration enhancer shielding and endosomal escape-kinetics crucial for efficient and biocompatible siRNA delivery.
Malfanti A; Sami H; Balasso A; Marostica G; Arpac B; Mastrotto F; Mantovani G; Cola E; Anton M; Caliceti P; Ogris M; Salmaso S
J Control Release; 2023 Nov; 363():101-113. PubMed ID: 37722420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
